Stock Price Quote

MEDICO REMEDIES LTD.

NSE : MEDICOBSE : 540937ISIN CODE : INE630Y01024Industry : Pharmaceuticals & DrugsHouse : Private
BSE46.87-0.3 (-0.64 %)
PREV CLOSE ( ) 47.17
OPEN PRICE ( ) 48.11
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 17952
TODAY'S LOW / HIGH ( )46.50 48.11
52 WK LOW / HIGH ( )44.95 100.79
NSE46.80-0.3 (-0.64 %)
PREV CLOSE( ) 47.10
OPEN PRICE ( ) 47.75
BID PRICE (QTY) 46.80 (15)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 66205
TODAY'S LOW / HIGH( ) 45.70 47.95
52 WK LOW / HIGH ( )44.55 100.7
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 18-03 1994
Management Info
Haresh Mehta - Chairman Harshit Mehta - Managing Director
Registered Office

Address 1105/1106, 11th Floor,Hubtown Solaris, Opp Telli Galli,N S Phadke Marg, Andheri East ,
Mumbai,
Maharashtra-400069

Phone 022 26821054 / 1055 / 26837116

Email medicoremedies@yahoo.com / info@medicoremedies.com

Website www.medicoremediesindia.com / www.medicoremediesindia.net / www.tabletandcapsules.com

Registrars Details
Cameo Corporate Services Ltd
304 Sai Sadan 3rd Floor,76 - 78 Mody Street,Fort,Mumbai
Listing : BSE, NSE

NEWS

22Mar Clarification sought from Medico Reme
The Exchange has sought clarification from Medico Remedies Ltd on March..
11Jan Medico Remedies informs about investor
Pursuant to Regulation 30 read with Part A of Schedule III of the SEBI (..
03Nov Medico Remedies informs about disclosu
Medico Remedies has informed that the exchange has received the disclosu..
23Oct Medico Remedies submits intimation of
With reference to disclosure submitted to the Stock Exchanges by the Pro..
11Aug Medico Remedies informs about newspape
In compliance with Regulation 47 of SEBI (Listing Obligations and Disclo..

Financials

in Millions
QTR Dec 23 ANNUAL 23
Net Profit14.4572.4299999999998
Gross Profit 20.63 101
Operating Profit 30.05135.67
Net Sales 297.721404.37

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Neuland Laboratories (BSE)
peergroup  6660.85 (7.79%)
M.Cap ( in Cr)8545.80
Concord Biotech (BSE)
peergroup  1561.65 (3.68%)
M.Cap ( in Cr)16337.39
Sanofi India (BSE)
peergroup  8490.90 (0.51%)
M.Cap ( in Cr)19555.07
JB Chem & Pharma (BSE)
peergroup  1800.50 (2.37%)
M.Cap ( in Cr)27942.82
Divi's Lab (BSE)
peergroup  3779.20 (1.08%)
M.Cap ( in Cr)100325.89

Shareholding Pattern

PROMOTERS 73.34%
NON-INSTITUTION 25.37%
MUTUAL FUNDS/UTI 0%
FI/BANKS/INSURANCE 0%
GOVERNMENT 0%
FII 0%

About Medico Remedies Ltd.

Medico Remedies Ltd. was incorporated in the year 1994. Its today's share price is 46.87. Its current market capitalisation stands at Rs 388.95 Cr. In the latest quarter, company has reported Gross Sales of Rs. 1404.37 Cr and Total Income of Rs.1445.23 Cr. The company's management includes Dinesh Navnitlal Modi, Deepesh Shah, Ramesh Rughani, Bharat Rathod, Deepak Vekaria, Rita Mehta, Rishit Mehta, Harshit Mehta, Haresh Mehta.

It is listed on the BSE with a BSE Code of 540937 , NSE with an NSE Symbol of MEDICO and ISIN of INE630Y01024. It's Registered office is at 1105/1106, 11th Floor,Hubtown Solaris, Opp Telli Galli,N S Phadke Marg, Andheri East Mumbai-400069, Maharashtra. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are Pratap R Rajwade, VJ Shah & Co

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.